Unmet needs in skin of color include satisfactory long-term treatments for hyperpigmentation, whether primary or a sequela of various dermatoses. Surveys report that pigmentary disorders are the second most common dermatoses among African American patients consulting dermatologists, and that hyperpigmentation significantly impairs quality of life. This single-center, open-label pilot evaluation prospectively assessed safety, efficacy and tolerability in patients with Fitzpatrick skin phototypes III to VI of an FDA 510(k)-cleared crystal-free brush-tip exfoliation device with adjustable vacuum pressure and skin infusion containing 1% each of alpha-arbutin, glutathione, kojic acid plus azelaic acid; lactic acid; and salix alba bark extract. 23 female patients aged 26 to 71 with mild, moderate or severe facial hyperpigmentation received 3 to 6 treatments at 2 to 4 weekly intervals. Patients applied broad spectrum sunscreen daily. Three weeks after the third treatment, blinded assessment of standardized digital images found that all patients had improvements in skin tone, texture and brightness/radiance (≥2 points on 10-point scales), and 15 (65%) had ≥1 point improvement in pigmentation. Physician and patient GAIS scoring ranged from Improved to Very Much Improved. DQLI improved for 12 (52%). The procedure was well tolerated, with no significant adverse effects. Post-procedural erythema lasted 15 minutes to under 24 hours. All patients reported satisfaction with treatment and increased These pilot data show safety, efficacy and tolerability in skin of color. The ability to patient-tailor all procedural steps, including exfoliation depth, magnitude of vacuum pressure and infusion type, may confer benefits over conventional aluminum oxide crystal microdermabrasion.